Health & Wellness

09/24/2026 · Kalkaska

FDA Authorizes Robotic Device for Automated Blood Draws

The U.S. Food and Drug Administration authorized a new robotic device, the Aletta, for automated blood draws. This system operates independently to collect blood from a patient's arm.

09/25/2026

Read Story

Health

Experimental Treatment Extends Cancer-Free Period in Clinical Trial

A recent clinical trial evaluated a novel jab designed to prevent cancer recurrence. Researchers observed that patients who received the treatment maintained a cancer-free status for an extended period. The exact long-term duration of this effect requires further investigation.

09/25/2026

Health

Study Links Aviation Careers to Increased Cancer Risk

A recent study found pilots and flight attendants experience higher mortality rates from cancers associated with cosmic radiation exposure. Researchers observed increased risks for specific cancer types among these aviation professionals. The findings highlight potential occupational health considerations for individuals working at high altitudes.

09/25/2026

Health

Study Links Recurring UTI Symptoms in Women to Inflammation, Pelvic Dysfunction

A recent study found that many women experiencing symptoms commonly associated with recurrent urinary tract infections did not, in fact, have UTIs. Instead, hormonally driven inflammation and pelvic floor dysfunction caused their symptoms. This research suggests a need for reevaluating diagnostic approaches.

09/25/2026

Health

Supreme Court Rules on Political Ad Rate Parity

The Supreme Court has ruled that national political party committees qualify for the lowest unit charge for broadcast advertising, matching the rates afforded to individual candidates. This decision stems from a challenge by the Republican National Committee and others, arguing for equal treatment under federal law.

09/25/2026

Health

Medicare Pilot Program Offers GLP-1 Discounts, Excludes Certain Patients

Medicare has initiated a pilot program to reduce the cost of GLP-1 medications for some beneficiaries to $50 per month. However, many individuals with significant health issues do not meet the program's eligibility requirements for this discount. This development affects access to these drugs for a segment of the Medicare population.

09/25/2026